Overview

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Status:
Completed
Trial end date:
2017-10-06
Target enrollment:
Participant gender:
Summary
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Polaris Group
Treatments:
Gemcitabine
Paclitaxel